恩度单药与恩度联合化疗腔内灌注治疗恶性胸腔积液的临床研究  

Clinical study of endostar on malignant cavity effusion

作　　者：赵文飞 孙翠萍 马晓燕 赵文文 张玲 王颂平 魏红梅 

机构地区：[1]青岛市中心(肿瘤)医院肿瘤综合治疗科,山东青岛266000

出　　处：《泰山医学院学报》2015年第10期1089-1092,共4页Journal of Taishan Medical College

基　　金：中国博士后科学基金资助项目(20090451574);中华国际医学交流基金资助项目(CIMF-F-H001-300);CSCO-先声抗肿瘤血管靶向治疗科研基金(Y-S2014-016;省级)

摘　　要：目的观察恩度单药、恩度联合顺铂与顺铂单药腔内灌注治疗恶性胸腔积液的疗效及安全性。方法选取54例恶性胸腔积液患者,采用腔内灌注药物治疗,其中恩度单药18例、恩度联合顺铂18例,单药顺铂18例。具体方法：恩度60 mg/次,q3d（d1、d4、d7）;顺铂60 mg/次（d2、d8）。21天为1周期,2个周期治疗后评价生活质量和VEGF,并按WHO胸腹水评价标准和NCI-CTC AE 3.0分级标准分别评价疗效和毒副反应。结果所有患者均完成2周期以上治疗,均能进行客观疗效及安全性评价。腔内恩度单药、联合化疗、腔内顺铂单药治疗的有效率分别为50.0%（CR 1例,PR 8例,SD 6例）、83.3%（CR 2例,PR 13例,SD 3例）和44.4%（CR 0例,PR 8例,SD 7例）。生活质量方面：联合组改善率最高,单药顺铂组最低。VEGF也以联合组下降最显著,单药顺铂组下降最少。3～4级毒副反应主要为白细胞减少、血小板减少、恶心呕吐和乏力,均发生在顺铂治疗组,无治疗相关性死亡发生。且恩度联合顺铂组与顺铂单药组在毒副反应方面差异无统计学意义。结论恩度单药腔内治疗恶性胸膜腔积液与单用顺铂疗效相当,两药联合疗效更优,且安全性好。Objective： To observe the efficacy and safety of endostar on malignant pleural effusion,in case to explore the influences of different combination modalities on efficacy initially. Methods： 54 patients with malignant pleural diagnosed were choosed. And they were randomly assigned into 3 groups,endostar group（ 60 mg / time on d1,d4,d7）; cisplatin group（ 60 mg / time on d2,d8）; combined group（ endostar 60 mg / time on d1,d4,d7; cisplatin 60 mg / time on d2,d8）. 21 days to 1 cycle,after 2 cycles of treatment,To evaluate the quality of life and VEGF. According to the WHO chest water evaluation standard and NCI-CTC AE 3. 0 classification standard evaluation of curative effect and adverse reaction,respectively. Results All patients completed treatment for more than 2 cycles,All able to objective curative effect and safety evaluation. Chest water control effectiveness in endostar group（ 50%,CR 1 case,PR 8 cases,SD 6 case）,combined group（ 83. 3%,CR 2 case,PR 13 cases,SD 3 case）,cisplatin group（ 44. 4%,CR 0 case,PR 8 cases,SD 7 case）.The quality of life： combined group have the highest efficiency,cisplatin group have the lowest efficiency. Grade 3 ～ 4main of adverse reaction as leukopenia,thrombocytopenia,nausea and vomiting,and All associated with cisplatin. no treatment-related deaths. Endostar combined with cisplatin without addition of adverse reaction. Conclusion Endostar single-agent have the similar effect with the cisplatin in the treatment of malignant pleural,at the same time,Two drug combination can raise the curative effect. Have good safety.

关 键 词：重组人血管内皮抑素/恩度 恶性胸膜腔积液 化疗 

分 类 号：R730.5[医药卫生—肿瘤]